Since VEGF is a critical downstream effector of hypoxia-driven HIF-1α activation and a key driver of neovascularization in endometrial cancer, its marked reduction suggests that BA and GEM may impair the vascular supply essential for tumor growth and survival. The gene discussed is HIF1A; the disease is endometrial cancer.